Role of Adiponectin in the metabolic syndrome: Current perspectives on its modulation as a treatment strategy

Current Pharmaceutical Design

Volumn 19, Issue 32, 2013, Pages 5755-5763

  Padmalayam, Indira ^a   Suto, Mark ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adiponectin; AMPK; Cardiovascular; Diabetes; Metabolic syndrome; Mitochondria; Obesity; PPAR

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ANTHOCYANIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ASCOFURANONE; ASTRAGALOSIDE II; ENDOCANNABINOID; FENOFIBRATE; GAMMA TOCOTRIENOL; INSULIN; ISOASTRAGALOSIDE I; ISOGINKGETIN; MULBERRY EXTRACT; NOBILITIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SOYMORPHIN 5; TELMISARTAN; THIOCTIC ACID; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CELL FUNCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; METABOLIC REGULATION; METABOLIC SYNDROME X; MITOCHONDRION; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY; PPAR ALPHA;

EID: 84876453239     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990360     Document Type: Review

References (73)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity J Biol Chem 1996; 271: 10697-703.
3. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
4. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996; 120: 803-12.
5. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-26.
6. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257: 560-4.
7. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
8. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
9. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-33.
10. Chen SJ, Yen CH, Huang YC, Lee BJ, Hsia S, Lin PT. Relationships between Inflammation, Adiponectin, and Oxidative Stress in Metabolic Syndrome. PLoS One. 2012; 7: e45693.
11. Hara K, Yamauchi T, Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep 2005; 5: 136-40.
12. Kumada M, Kihara S, Sumitsuji S, et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
13. Komura N, Kihara S, Sonoda M, et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008; 72: 23-8. Erratum in: Circ J 2008; 72(3): 508.
14. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
15. Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/ Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord. 2003; 3(4): 243-54
16. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-8.
17. Otabe S, Yuan X, Fukutani T, et al. Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 2007; 293: E210-8.
18. Patel SA, Hoehn KL, Lawrence RT, et al. Overexpression of the Adiponectin Receptor AdipoR1 in Rat Skeletal Muscle Amplifies Local Insulin Sensitivity. Endocrinology 2012; Sep 18. [Epub ahead of print]
19. Gu W, Li Y. The therapeutic potential of the adiponectin pathway. BioDrugs 2012; 26: 1-8.
20. Rao JR, Keating DJ, Chen C, Parkington HC. Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms. Diabetes Obes Metab 2012; 14: 983-9.
21. Okamoto Y. Adiponectin provides cardiovascular protection in metabolic syndrome Cardiol Res Pract 2011; 2011: 313179
22. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
23. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-70.
24. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33: 547-94.
25. Delort L, Jardé T, Dubois V, Vasson MP, Caldefie-Chézet F. New insights into anticarcinogenic properties of adiponectin: a potential therapeutic approach in breast cancer? Vitam Horm 2012; 90: 397-417.
26. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-63.
27. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008; 409: 623-33.
28. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-10.
29. Waki H, Yamauchi T, Kamon J, et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 2005; 146: 790-6.
30. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and antiatherogenic properties of adiponectin. Biochimie 2012; 94: 2137-42.
31. Kacso IM, Bondor CI, Kacso G. Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients. Scand J Clin Lab Invest 2012; 72: 333-9.
32. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
33. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55-63.
34. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010; 285; 33623-31.
35. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003 Jun 12; 423(6941): 762-9. Erratum in: Nature. 2004 Oct 28; 431(7012): 1123.
36. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-9.
37. Kadowaki, T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Letters 2008; 582: 74-80.
38. Pita J, Panadero A, Soriano-Guillén L, Rodríguez E, Rovira A. The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regul Pept 2012; 174: 18-25.
39. Mori H, Okada Y, Arao T, Nishida K, Tanaka Y. Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. Adv Ther 2012; 29: 635-44.
40. Xu A, Wang H, Hoo RL, et al. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009; 150: 625-33.
41. Shiota A, Shimabukuro M, Fukuda D, et al. Activation of AMPKSirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. Eur J Pharmacol 2012; 692: 84-90.
42. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
43. Yamada Y, Muraki A, Oie M, et al. Soymorphin-5, a soy-derived μ-opioid peptide, decreases glucose and triglyceride levels through activating adiponectin and PPARα systems in diabetic KKAy mice. Am J Physiol Endocrinol Metab 2012; 302: E433-40.
44. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291: E1100-5.
45. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-71.
46. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010; 464: 1313-9.
47. Qiao L, Kinney B, Yoo HS, Lee B, Schaack J, Shao J. Adiponectin increases skeletal muscle mitochondrial biogenesis by suppressing mitogen-activated protein kinase phosphatase-1. Diabetes 2012; 61: 1463-70.
48. Zhou M, Xu A, Tam PK, et al. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008; 48: 1087-96.
49. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin Induces Pro-Inflammatory Programs in Human Macrophages and CD4+ T Cells J Biol Chem 2012; Sep 4. [Epub ahead of print]
50. Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. FEBS Lett 2010; 584: 4280-6.
51. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. Tcadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004; 101: 10308-13.
52. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010; 120: 4342-52.
53. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30: 234-9.
54. Shen X, Li H, Li W, Wu X, Ding X. Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs. Mol Cell Endocrinol 2012; 363: 27-35.
55. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007 Feb 6; 49(5): 531-8.
56. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-14.
57. Ge Q, Maury E, Rycken L, et al. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. Int J Obes 2012 [Epub ahead of print]
58. Watanabe T, Kubota N, Ohsugi M, et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectinindependent pathways. J Biol Chem 2009; 284: 1803-12.
59. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
60. Liu G, Grifman M, Macdonald J, Moller P, Wong-Staal F, Li QX. Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase. J Endocrinol 2007; 194: 569-78.
61. Moreno JA, Hong E. A single oral dose of fructose induces some features of metabolic syndrome in rats: Role of oxidative stress. Nutr Metab Cardiovasc Dis. 2012; Feb 29. [Epub ahead of print]
62. Padmalayam, I. Targeting mitochondrial oxidative stress through lipoic acid synthase: a novel strategy to manage diabetic cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2012; 10: 223-33.
63. Mi{dotless}ci{dotless}li{dotless} SC, Ergur BU, Ozoǧul C, et al. Effects of Lipoic Acid in an Experimentally Induced Hypertensive and Diabetic Rat Model. Clin Exp Hypertens. 2012; Oct 16. [Epub ahead of print]
64. Jung TS, Kim SK, Shin HJ, Jeon BT, Hahm JR, Roh GS. α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats. Liver Int 2012; 32: 1565-73.
65. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Martínez JA, Moreno-Aliaga MJ. Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low-and high-fat-fed rats. Eur J Nutr 2012; Jun 5. [Epub ahead of print]
66. Tsuda T, Ueno Y, Aoki H, et al. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem Biophys Res Commun 2004; 316: 149-57.
67. Chang YC, Cho HJ. Ascofuranone stimulates expression of adiponectin and peroxisome proliferator activated receptor through the modulation of mitogen activated protein kinase family members in 3T3-L1, murine pre-adipocyte cell line. Biochem Biophys Res Commun 2012; 422: 423-8.
68. Matsunaga T, Shoji A, Gu N, et al. γ-Tocotrienol attenuates TNF-α-induced changes in secretion and gene expression of MCP-1, IL-6 and adiponectin in 3T3-L1 adipocytes. Mol Med Report 2012; 5: 905-9.
69. Kunimasa K, Kuranuki S, Matsuura N, et al. Identification of nobiletin, a polymethoxy flavonoid, as an enhancer of adiponectin secretion. Bioorg Med Chem Lett 2009; 19: 2062-4.
70. Naowaboot J, Chung CH, Pannangpetch P, et al. Mulberry leaf extract increases adiponectin in murine 3T3-L1 adipocytes. Nutr Res. 2012; 32: 39-44.
71. Hino K, Nagata H, Shimonishi M, Ido M. High-throughput screening for small-molecule adiponectin secretion modulators. J Biomol Screen 2011; 16: 628-36.
72. Otvos L Jr, Haspinger E, La Russa F, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 2011; 11: 90.
73. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.